• 江南·体育(JN SPORTS)官方网站,江南体育app下载

    |
    |
    EN
    • 业务咨询

      中国:

      Email: marketing@hangzhouaijunshengwu.com

      业务咨询专线:400-780-8018

      (仅限服务咨询,其他事宜请拨打川沙总部电话)

      川沙总部电话: +86 (21) 5859-1500

      海外:

      +1(626)986-9880(U.S. - West Coast)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com

    在线留言×
    点击切换

    搜索结果包含 Christmas Greeting From MEDICILON 的内容

    Oct 19,2023
    欧洲见!美迪西戴学东博士邀您一起探索药物发现的创新与未来
    美迪西戴学东博士将参加欧洲ELRIG Drug Discovery 会议,并带来超专业的精彩演讲“CHEMISTRY ENABLING DRUG DISCOVERY FROM START TO CLINIC”。
    查看更多
    欧洲见!美迪西戴学东博士邀您一起探索药物发现的创新与未来
    Oct 10,2023
    美迪西助力备受瞩目,第21届圣地亚哥生物制药论坛圆满落幕
    2023年9月30日中秋佳节,南加生物医学和制药促进会 (SABPA)成功举办了第21届圣地亚哥生物制药论坛,陈春麟博士受邀发表了“Retrospective Studies on New Drug Research in China based on IND Approval Cases at Medicilon”精彩演讲。
    查看更多
    美迪西助力备受瞩目,第21届圣地亚哥生物制药论坛圆满落幕
    Sep 25,2023
    9月30日,美迪西陈春麟博士将出席第21届圣地亚哥生物制药大会
    美迪西创始人&CEO陈春麟博士将出席第21届圣地亚哥生物制药大会,并带来主题演讲:“Retrospective Studies on New Drug Research in China based on IND Approval Cases at Medicilon”
    查看更多
    9月30日,美迪西陈春麟博士将出席第21届圣地亚哥生物制药大会
    Jul 06,2023
    基于构效关系分析,合成了一种结构简化但具有优异防污活性的化合物。优化后的化合物通过美迪西合成
    Biofouling poses one of the most serious problems to marine industry and aquaculture development. Five structurally similar compounds were isolated from the crude extract of a marine Streptomyces stra
    查看更多
    基于构效关系分析,合成了一种结构简化但具有优异防污活性的化合物。优化后的化合物通过美迪西合成
    Jul 06,2023
    Columbin具有多种药理活性,包括体内抗炎和抗肿瘤活性,此实验中动物研究通过美迪西进行
    Columbin is an important component isolated from Radix Tinosporae. Columbin possesses many pharmacological activities, including anti-inflammation, and antitumor activity in vivo. The purpose of the p
    查看更多
    Columbin具有多种药理活性,包括体内抗炎和抗肿瘤活性,此实验中动物研究通过美迪西进行
    Jul 06,2023
    AD80是一种多激酶抑制剂,在多种肝细胞癌临床前动物模型中具有抗肿瘤活性,AD80在血浆中的含量通过美迪西进行LC-MS/MS测定
    Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models
    查看更多
    AD80是一种多激酶抑制剂,在多种肝细胞癌临床前动物模型中具有抗肿瘤活性,AD80在血浆中的含量通过美迪西进行LC-MS/MS测定
    Jun 28,2023
    SAHA可有效恢复阿尔茨海默病模型的记忆能力,本研究中SAHA通过美迪西合成
    SAHA was synthesized by Medicilon and was given to mice as 50 mg/kg doses. Injections (10 mL/kg) were given intraperitoneally and were alternated daily between left and right sides of the abdomen. Chronic treatments of SAHA completely restored performance
    查看更多
    SAHA可有效恢复阿尔茨海默病模型的记忆能力,本研究中SAHA通过美迪西合成
    Jun 28,2023
    TAK-243是一种有效的泛素激活酶小分子抑制剂,具有体内抗肿瘤功效,通过美迪西使用HCC70模型进行
    TAK-243 is a potent, mechanism-based small-molecule inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade. TAK-243 has UAE-specific antitumor efficacy in vivo. Medicilon perfor
    查看更多
    TAK-243是一种有效的泛素激活酶小分子抑制剂,具有体内抗肿瘤功效,通过美迪西使用HCC70模型进行
    Jun 28,2023
    法尼基转移酶抑制剂LNK-754单次口服后即可快速穿过血脑屏障,PK分析通过美迪西进行
    Pharmacokinetic studies revealed that after a single oral dose, the FTI (LNK-754) was cleared from plasma within 20 hours and could rapidly cross the blood-brain-barrier. Pharmacokinetic analysis was performed as a service provided by Medicilon.
    查看更多
    法尼基转移酶抑制剂LNK-754单次口服后即可快速穿过血脑屏障,PK分析通过美迪西进行
    Jun 28,2023
    WYC-209可抑制恶性小鼠黑色素瘤肿瘤再生细胞增殖,SPR分析通过美迪西使用Biacore 8K设备进行
    The binding assay by surface plasmon resonance (SPR) analysis shows that WYC-209A and WYC-209B acid bind to RARs at nano-molar doses. SPR was carried out by Medicilon, using the Biacore 8K equipment.
    查看更多
    WYC-209可抑制恶性小鼠黑色素瘤肿瘤再生细胞增殖,SPR分析通过美迪西使用Biacore 8K设备进行
    Jun 28,2023
    ARD-2128是一种PROTAC AR降解剂,具有出色的血浆和微粒体稳定性,体外稳定性和PK研究通过美迪西进行
    ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.
    查看更多
    ARD-2128是一种PROTAC AR降解剂,具有出色的血浆和微粒体稳定性,体外稳定性和PK研究通过美迪西进行
    Jun 28,2023
    开发并验证新的LC-MS/MS方法,用于定量人血浆中达拉非尼及其主要代谢物羟基达拉非尼 (OHD)。OHD(纯度>99%)通过美迪西合成
    OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
    查看更多
    开发并验证新的LC-MS/MS方法,用于定量人血浆中达拉非尼及其主要代谢物羟基达拉非尼 (OHD)。OHD(纯度>99%)通过美迪西合成
    Jun 28,2023
    放射疗法用作肺癌的主要治疗方法,在次研究中建立抗电离辐射肺癌细胞系的放射治疗通过美迪西进行
    Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.
    查看更多
    放射疗法用作肺癌的主要治疗方法,在次研究中建立抗电离辐射肺癌细胞系的放射治疗通过美迪西进行
    Jun 28,2023
    索拉非尼的无定形固体分散体用于开发改良型口服生物利用度高的速释片剂,PK研究通过美迪西进行
    The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar®. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar® tablets was performed by Medicilon.
    查看更多
    索拉非尼的无定形固体分散体用于开发改良型口服生物利用度高的速释片剂,PK研究通过美迪西进行
    Jun 28,2023
    TAK-931是一种高度特异性的CDC7抑制剂,具有抗肿瘤功效,体内药效研究通过美迪西进行
    In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.
    查看更多
    TAK-931是一种高度特异性的CDC7抑制剂,具有抗肿瘤功效,体内药效研究通过美迪西进行
    Jun 28,2023
    GS-5801是一种有效的KDM5抑制剂,具有抗HBV活性,GS-5801通过美迪西合成
    GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
    查看更多
    GS-5801是一种有效的KDM5抑制剂,具有抗HBV活性,GS-5801通过美迪西合成
    Jun 28,2023
    QF-036是一种高效的HIV-1抑制剂,具有良好的和药代动力学特性,PK研究通过美迪西进行
    The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.
    查看更多
    QF-036是一种高效的HIV-1抑制剂,具有良好的和药代动力学特性,PK研究通过美迪西进行
    Jun 28,2023
    SKLB-197是一种有效且高度选择性的ATR抑制剂,PK研究通过美迪西进行
    SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.
    查看更多
    SKLB-197是一种有效且高度选择性的ATR抑制剂,PK研究通过美迪西进行
    Jun 28,2023
    JND003是一种新型选择性ERRα激动剂,可缓解非酒精性脂肪肝和胰岛素抵抗,PK和组织分布测定通过美迪西进行
    JND003 is orally bioavailable and exhibits high grade of distribution in liver and abdominal adipose tissues. Pharmacokinetics (PK) and Tissue Distribution Assays of JND003 were performed at Medicilon.
    查看更多
    JND003是一种新型选择性ERRα激动剂,可缓解非酒精性脂肪肝和胰岛素抵抗,PK和组织分布测定通过美迪西进行
    May 29,2023
    美研 | Beautiful Chemistry Issue 4 : Direct Cyclopropanation by Organoelectrocatalysis
    In summary, the efficient and scalable intramolecular cyclopropanation of active methylene compounds via electrocatalysis with an organic catalyst can solve challenges from the transition metal catalyzed alkene cyclopropanation of functionalized compound
    查看更多
    美研 | Beautiful Chemistry Issue 4 : Direct Cyclopropanation by Organoelectrocatalysis
    江南·体育(JN SPORTS)官方网站